{"id":{"repo_id":"mcmaster","oai_identifier":"oai:macsphere.mcmaster.ca:11375/32649"},"canonical_url":"https://search.ndltd.org/etd/mcmaster/oai:macsphere.mcmaster.ca:11375/32649","repository":{"repo_id":"mcmaster","name":"McMaster University","base_url":"https://macsphere.mcmaster.ca/server/oai/request"},"display":{"title":"THE CAUSAL RELATIONSHIP BETWEEN CIRCULATING PAM LEVELS AND RISK OF TYPE 2 DIABETES: A MENDELIAN RANDOMIZATION STUDY","abstract":"Background/Hypothesis: Research into the biological mechanisms of type 2 diabetes (T2D) have unveiled new genes and proteins associated with the disease. One of these discoveries was peptidylglycine α-amidating monooxygenase (PAM), in which loss of function alleles have been associated with increased T2D risk and its deficiency was shown to lower insulin secretion in-vivo. However, the question of whether PAM modulates insulin secretion in humans has gone unanswered. Using the genetic inference method 2-sample Mendelian randomization (MR), we hypothesized that decreased circulating PAM protein would increase T2D risk by lowering insulin secretion and causing increased post-prandial glucose levels. Methodology: We created PAM instrumental variables (IVs) from a meta-analysis of protein quantitative trait loci from European subsets of the UK Biobank (N=34,557) and the Prospective Urban and Rural Epidemiological Study (N=3,735). The PAM IVs were tested against single nucleotide polymorphisms associated with a total of 18 traits, including T2D from different populations, early onset T2D, glycated haemoglobin, and three blood glucose measurements of varying stratifications. Results: MR analyses confirmed that 1 SD decrease in genetically predicted PAM circulating levels was associated with increased T2D risk, both with adjustment for BMI (OR per 1 SD decrease PAM = 1.14; 95% CI, 1.11 to 1.16; P=7.64×10-25), and without (OR per 1 SD decrease PAM = 1.13; 95% CI, 1.10 to 1.15; P=1.84×10-31). FG showed consistent decrease of FG in response to PAM levels (mmol/L FG change per 1 SD decrease PAM = -0.014; 95% CI, -0.019 to -0.009; P=2.08×10-8) while post-prandial 2hGlu increased (mmol/L FG change per 1 SD decrease PAM = 0.057; 95% CI, 0.021 to 0.093; P=1.98×10-3). Conclusion: Using 2-sample MR, PAM deficiency was reconfirmed to increase T2D risk and newly found to increase postprandial glucose. Enhancement of circulating PAM level may be a promising therapeutic prospect in the solution of diabetes prevention and treatment.","abstract_html":"Background/Hypothesis: Research into the biological mechanisms of type 2 diabetes (T2D) have unveiled new genes and proteins associated with the disease. One of these discoveries was peptidylglycine α-amidating monooxygenase (PAM), in which loss of function alleles have been associated with increased T2D risk and its deficiency was shown to lower insulin secretion in-vivo. However, the question of whether PAM modulates insulin secretion in humans has gone unanswered. Using the genetic inference method 2-sample Mendelian randomization (MR), we hypothesized that decreased circulating PAM protein would increase T2D risk by lowering insulin secretion and causing increased post-prandial glucose levels. Methodology: We created PAM instrumental variables (IVs) from a meta-analysis of protein quantitative trait loci from European subsets of the UK Biobank (N=34,557) and the Prospective Urban and Rural Epidemiological Study (N=3,735). The PAM IVs were tested against single nucleotide polymorphisms associated with a total of 18 traits, including T2D from different populations, early onset T2D, glycated haemoglobin, and three blood glucose measurements of varying stratifications. Results: MR analyses confirmed that 1 SD decrease in genetically predicted PAM circulating levels was associated with increased T2D risk, both with adjustment for BMI (OR per 1 SD decrease PAM = 1.14; 95% CI, 1.11 to 1.16; P=7.64×10-25), and without (OR per 1 SD decrease PAM = 1.13; 95% CI, 1.10 to 1.15; P=1.84×10-31). FG showed consistent decrease of FG in response to PAM levels (mmol/L FG change per 1 SD decrease PAM = -0.014; 95% CI, -0.019 to -0.009; P=2.08×10-8) while post-prandial 2hGlu increased (mmol/L FG change per 1 SD decrease PAM = 0.057; 95% CI, 0.021 to 0.093; P=1.98×10-3). Conclusion: Using 2-sample MR, PAM deficiency was reconfirmed to increase T2D risk and newly found to increase postprandial glucose. Enhancement of circulating PAM level may be a promising therapeutic prospect in the solution of diabetes prevention and treatment.","abstract_has_math":false,"creators":["Feiner, James"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":"Biochemistry and Biomedical Sciences","school":null,"contributors":[],"advisors":["Pigeyre, Marie"],"committee_chairs":[],"committee_members":[],"year":2026,"date_issued":"2026","date_published":"2026","updated_at":"2026-11-19T05:57:42Z","subjects":["T2D","Peptidylglycine α-amidating monooxygenase","Mendelian randomization","genetics","post-prandial glucose","insulin secretion","biomarker","glucose regulation"],"languages":["en_US"],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://doi.org/10.71548/16293"],"render_values":[{"text":"https://doi.org/10.71548/16293","href":"https://doi.org/10.71548/16293","code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"https://hdl.handle.net/11375/32649","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"https://hdl.handle.net/11375/32649","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://macsphere.mcmaster.ca/server/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Amacsphere.mcmaster.ca%3A11375%2F32649","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Pigeyre, Marie"]},{"key":"dc:contributor.department","label":"Department","values":["Biochemistry and Biomedical Sciences"]},{"key":"dc:creator","label":"Author","values":["Feiner, James"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2025-12-02T20:13:10Z"]},{"key":"dc:date.issued","label":"Date","values":["2026"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["T2D","Peptidylglycine α-amidating monooxygenase","Mendelian randomization","genetics","post-prandial glucose","insulin secretion","biomarker","glucose regulation"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en_US"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/11375/32649","https://doi.org/10.71548/16293"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Background/Hypothesis: Research into the biological mechanisms of type 2 diabetes (T2D) have unveiled new genes and proteins associated with the disease. One of these discoveries was peptidylglycine α-amidating monooxygenase (PAM), in which loss of function alleles have been associated with increased T2D risk and its deficiency was shown to lower insulin secretion in-vivo. However, the question of whether PAM modulates insulin secretion in humans has gone unanswered. Using the genetic inference method 2-sample Mendelian randomization (MR), we hypothesized that decreased circulating PAM protein would increase T2D risk by lowering insulin secretion and causing increased post-prandial glucose levels. Methodology: We created PAM instrumental variables (IVs) from a meta-analysis of protein quantitative trait loci from European subsets of the UK Biobank (N=34,557) and the Prospective Urban and Rural Epidemiological Study (N=3,735). The PAM IVs were tested against single nucleotide polymorphisms associated with a total of 18 traits, including T2D from different populations, early onset T2D, glycated haemoglobin, and three blood glucose measurements of varying stratifications. Results: MR analyses confirmed that 1 SD decrease in genetically predicted PAM circulating levels was associated with increased T2D risk, both with adjustment for BMI (OR per 1 SD decrease PAM = 1.14; 95% CI, 1.11 to 1.16; P=7.64×10-25), and without (OR per 1 SD decrease PAM = 1.13; 95% CI, 1.10 to 1.15; P=1.84×10-31). FG showed consistent decrease of FG in response to PAM levels (mmol/L FG change per 1 SD decrease PAM = -0.014; 95% CI, -0.019 to -0.009; P=2.08×10-8) while post-prandial 2hGlu increased (mmol/L FG change per 1 SD decrease PAM = 0.057; 95% CI, 0.021 to 0.093; P=1.98×10-3). Conclusion: Using 2-sample MR, PAM deficiency was reconfirmed to increase T2D risk and newly found to increase postprandial glucose. Enhancement of circulating PAM level may be a promising therapeutic prospect in the solution of diabetes prevention and treatment."]},{"key":"dc:description.abstractgeneral","label":"General Abstract","values":["Affecting hundreds of millions of people worldwide, type 2 diabetes (T2D) is a chronic disease where the regulation of blood sugar in the body is compromised. While many of the causes of T2D are well characterized, individuals have different susceptibilities to these risk factors and responses to treatment. This has driven scientists to try to further understand the underlying genetic and biochemical mechanisms in T2D. Over the past 25 years, many genes have been found to contribute to the development of T2D, though how exactly many of these genes and their protein products are involved in the disease is not fully understood. Recent research had identified disruption of the gene for peptidylglycine α-amidating monooxygenase (PAM) was linked to increased risk of developing T2D. Experiments in cell and animal models had also shown that the PAM protein was involved with the mechanism to secrete insulin, a hormone that lowers blood sugar after a meal. Seeking to replicate these findings in humans, we used the genetic inference technique Mendelian randomization to test how genetically predicted PAM concentration affected risk of T2D and regulation of blood sugar. We found that lower genetically predicted concentration PAM caused a 14% increased risk of T2D, raised the concentration of postprandial blood sugar by 0.057 mmol/L, and lowered the concentration of fasting blood sugar by -0.014 mmol/L. These findings confirmed that PAM plays a role in blood sugar regulation and T2D development in humans, but further research is needed to uncover additional protein and metabolite interactions."]},{"key":"dc:description.degree","label":"Dc Description Degree","values":["Master of Science (MSc)"]},{"key":"dc:title","label":"Title","values":["THE CAUSAL RELATIONSHIP BETWEEN CIRCULATING PAM LEVELS AND RISK OF TYPE 2 DIABETES: A MENDELIAN RANDOMIZATION STUDY"]},{"key":"dc:title.alternative","label":"Alternative Title","values":["CIRCULATING PAM LEVELS AND RISK OF TYPE 2 DIABETES"]},{"key":"others:access_status","label":"Others Access Status","values":["open.access"]}]}],"canonical_facts":{"dc:contributor.advisor":["Pigeyre, Marie"],"dc:contributor.department":["Biochemistry and Biomedical Sciences"],"dc:creator":["Feiner, James"],"dc:date.accessioned":["2025-12-02T20:13:10Z"],"dc:date.issued":["2026"],"dc:description.abstract":["Background/Hypothesis: Research into the biological mechanisms of type 2 diabetes (T2D) have unveiled new genes and proteins associated with the disease. One of these discoveries was peptidylglycine α-amidating monooxygenase (PAM), in which loss of function alleles have been associated with increased T2D risk and its deficiency was shown to lower insulin secretion in-vivo. However, the question of whether PAM modulates insulin secretion in humans has gone unanswered. Using the genetic inference method 2-sample Mendelian randomization (MR), we hypothesized that decreased circulating PAM protein would increase T2D risk by lowering insulin secretion and causing increased post-prandial glucose levels. Methodology: We created PAM instrumental variables (IVs) from a meta-analysis of protein quantitative trait loci from European subsets of the UK Biobank (N=34,557) and the Prospective Urban and Rural Epidemiological Study (N=3,735). The PAM IVs were tested against single nucleotide polymorphisms associated with a total of 18 traits, including T2D from different populations, early onset T2D, glycated haemoglobin, and three blood glucose measurements of varying stratifications. Results: MR analyses confirmed that 1 SD decrease in genetically predicted PAM circulating levels was associated with increased T2D risk, both with adjustment for BMI (OR per 1 SD decrease PAM = 1.14; 95% CI, 1.11 to 1.16; P=7.64×10-25), and without (OR per 1 SD decrease PAM = 1.13; 95% CI, 1.10 to 1.15; P=1.84×10-31). FG showed consistent decrease of FG in response to PAM levels (mmol/L FG change per 1 SD decrease PAM = -0.014; 95% CI, -0.019 to -0.009; P=2.08×10-8) while post-prandial 2hGlu increased (mmol/L FG change per 1 SD decrease PAM = 0.057; 95% CI, 0.021 to 0.093; P=1.98×10-3). Conclusion: Using 2-sample MR, PAM deficiency was reconfirmed to increase T2D risk and newly found to increase postprandial glucose. Enhancement of circulating PAM level may be a promising therapeutic prospect in the solution of diabetes prevention and treatment."],"dc:description.abstractgeneral":["Affecting hundreds of millions of people worldwide, type 2 diabetes (T2D) is a chronic disease where the regulation of blood sugar in the body is compromised. While many of the causes of T2D are well characterized, individuals have different susceptibilities to these risk factors and responses to treatment. This has driven scientists to try to further understand the underlying genetic and biochemical mechanisms in T2D. Over the past 25 years, many genes have been found to contribute to the development of T2D, though how exactly many of these genes and their protein products are involved in the disease is not fully understood. Recent research had identified disruption of the gene for peptidylglycine α-amidating monooxygenase (PAM) was linked to increased risk of developing T2D. Experiments in cell and animal models had also shown that the PAM protein was involved with the mechanism to secrete insulin, a hormone that lowers blood sugar after a meal. Seeking to replicate these findings in humans, we used the genetic inference technique Mendelian randomization to test how genetically predicted PAM concentration affected risk of T2D and regulation of blood sugar. We found that lower genetically predicted concentration PAM caused a 14% increased risk of T2D, raised the concentration of postprandial blood sugar by 0.057 mmol/L, and lowered the concentration of fasting blood sugar by -0.014 mmol/L. These findings confirmed that PAM plays a role in blood sugar regulation and T2D development in humans, but further research is needed to uncover additional protein and metabolite interactions."],"dc:description.degree":["Master of Science (MSc)"],"dc:identifier.uri":["https://hdl.handle.net/11375/32649","https://doi.org/10.71548/16293"],"dc:language.iso":["en_US"],"dc:subject":["T2D","Peptidylglycine α-amidating monooxygenase","Mendelian randomization","genetics","post-prandial glucose","insulin secretion","biomarker","glucose regulation"],"dc:title":["THE CAUSAL RELATIONSHIP BETWEEN CIRCULATING PAM LEVELS AND RISK OF TYPE 2 DIABETES: A MENDELIAN RANDOMIZATION STUDY"],"dc:title.alternative":["CIRCULATING PAM LEVELS AND RISK OF TYPE 2 DIABETES"],"dc:type":["Thesis"],"others:access_status":["open.access"]},"updated_at":"2026-11-19T05:57:42Z"}